Balaji Prasad
Stock Analyst at Barclays
(2.83)
# 1,730
Out of 5,152 analysts
147
Total ratings
49.59%
Success rate
5.27%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $5.66 | +341.70% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $13.26 | -17.04% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $22.86 | +4.99% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $14.53 | -38.06% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $183.63 | +8.91% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $23.92 | -20.57% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $74.90 | -19.89% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $122.23 | +99.62% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $6.71 | +257.68% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $49.59 | -55.64% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $618.92 | -15.98% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $31.75 | -18.11% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $160 | $206.27 | -22.43% | 15 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $14.27 | +19.13% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $4.16 | +332.69% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $4.23 | +136.41% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $1.76 | +297.73% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $5.66
Upside: +341.70%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $13.26
Upside: -17.04%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $22.86
Upside: +4.99%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $14.53
Upside: -38.06%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $183.63
Upside: +8.91%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $23.92
Upside: -20.57%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $74.90
Upside: -19.89%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $122.23
Upside: +99.62%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $6.71
Upside: +257.68%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $49.59
Upside: -55.64%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $618.92
Upside: -15.98%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $31.75
Upside: -18.11%
Dec 16, 2024
Maintains: Overweight
Price Target: $150 → $160
Current: $206.27
Upside: -22.43%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $14.27
Upside: +19.13%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $4.16
Upside: +332.69%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $4.23
Upside: +136.41%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $1.76
Upside: +297.73%